miRNA-214 to predict progression and survival in ALS.

Area of Science:

• Neuroscience
• Biomarker Discovery
• Molecular Biology

Background:

• Reliable biomarkers are crucial for predicting amyotrophic lateral sclerosis (ALS) progression and prognosis.
• NCK-associated protein 1 (NCKAP1) was previously identified as a key factor in defective phagocytosis in ALS patient-derived microglia.
• This study investigates the role of microRNA-214 (miRNA-214), a target of NCKAP1, in ALS progression.

Purpose of the Study:

• To explore the role of miRNA-214 in the progression of amyotrophic lateral sclerosis (ALS).
• To determine if plasma miRNA-214 levels can predict disease progression speed and survival time in ALS patients.

Main Methods:

• A discovery cohort (n=29) was used to identify miRNA-214 targeting NCKAP1.
• A validation cohort (n=132) assessed the clinical utility of miRNA-214 for predicting ALS progression and survival.

Main Results:

• Increased plasma and iMG miRNA-214 levels were observed in rapidly progressive ALS participants.
• Plasma miRNA-214 levels correlated with ALS disease progression, severity, and survival, differentiating rapid vs. slow progression.
• miRNA-214 levels correlated with plasma neurofilament light chain (NfL) and MCP-1, improving survival prediction accuracy when combined with NfL or MCP-1.

Conclusions:

• Plasma miRNA-214 demonstrates potential as a novel biomarker for predicting ALS progression and prognosis.
• miRNA-214 may offer a valuable tool for stratifying ALS patients based on disease trajectory.